Stay updated on CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial
Sign up to get notified when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.

Latest updates to the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedRevision tag updated from v3.5.3 to v3.5.4, indicating a new version of the page. This update is at the metadata level and does not modify the study details or user-facing content.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe page’s revision/version indicator was updated from v3.5.0 to v3.5.3, reflecting a site release rather than a change to the clinical trial information.SummaryDifference0.0%

- Check59 days agoChange DetectedAdded Squamous cell carcinoma of the head and neck to the conditions and included the Genetic and Rare Diseases Information Center as a new resource.SummaryDifference0.1%

- Check67 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check81 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check96 days agoChange DetectedNo substantive additions or deletions were detected in the study details; the page content remains the same.SummaryDifference0.0%

Stay in the know with updates to CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CIMAvax, Nivolumab & Pembrolizumab in Advanced Cancer Clinical Trial page.